Repligen Corp revenue by segment RGEN

Annual Quarterly

Repligen Corp splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Filtration Products at $402.8 million, 55% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	806	738	634	632	802	671	366	270	194	141	105
Filtration Products	—	403 +8.0% share 54.6%	373 +9.3% share 58.8%	341 -31.2% share 54.0%	496 +22.9% share 61.9%	404 +130.8% share 60.2%	175 +46.4% share 47.7%	119 +31.9% share 44.2%	91 +84.7% share 46.7%	49 share 34.7%	—
Chromatography Products	—	153 +24.7% share 20.7%	123 -3.0% share 19.4%	127 -3.8% share 20.0%	132 +44.6% share 16.4%	91 +28.8% share 13.6%	71 +16.5% share 19.3%	61 +33.8% share 22.4%	45 +24.8% share 23.4%	36 share 25.7%	—
Proteins Products	—	97 +30.9% share 13.2%	74 -28.1% share 11.7%	103 -9.5% share 16.4%	114 -7.6% share 14.3%	124 +48.5% share 18.4%	83 +20.7% share 22.7%	69 +26.9% share 25.5%	54 +0.8% share 28.0%	54 share 38.2%	—
Process Analytics Products	—	81 +37.0% share 11.0%	59 +4.4% share 9.3%	57 +6.2% share 9.0%	54 +11.4% share 6.7%	48 +44.0% share 7.2%	33 +103.3% share 9.1%	16 share 6.1%	—	—	—
Other Products	—	3 -29.0% share 0.4%	5 +26.9% share 0.7%	4 -35.8% share 0.6%	6 +41.7% share 0.7%	4 +2.7% share 0.6%	4 -13.5% share 1.1%	5 +26.6% share 1.7%	4 +104.7% share 1.9%	2 share 1.2%	—
Royalty	—	0 +13.4% share 0.0%	0 -31.9% share 0.0%	0 +8.5% share 0.1%	0 +64.2% share 0.0%	0 +73.4% share 0.0%	0 -16.2% share 0.0%	0 +5.0% share 0.1%	0 -4.1% share 0.1%	0 share 0.1%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: RGEN (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Waltham, MA
SEC filer status: Large accelerated filer
SEC CIK: 730272

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.